- Trials with a EudraCT protocol (329)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
329 result(s) found for: Phase variation.
Displaying page 1 of 17.
EudraCT Number: 2015-005685-30 | Sponsor Protocol Number: 2015-005685-30 | Start Date*: 2016-04-08 |
Sponsor Name:Hôpital Erasme | ||
Full Title: Evaluation of microcirculation alterations in cardiac surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and biological analysis | ||
Medical condition: Cardiac pathology eligible for surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004527-36 | Sponsor Protocol Number: PILOT_EGP | Start Date*: 2014-01-10 |
Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel | ||
Full Title: An open, non-randomized, single-center pilotstudy investigating the feasibility of determining the endogenous glucose production during a hypoglycaemic clamp in type 1 diabetes mellitus subjects | ||
Medical condition: Diabetes Mellitus Type 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003661-18 | Sponsor Protocol Number: 2014-878 | Start Date*: 2015-09-29 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of choroidal neovascularization complicating angioid streaks in young subjects: the ASTRID study | |||||||||||||
Medical condition: choroidal neovascularization complicating angioid streaks | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002731-28 | Sponsor Protocol Number: P12-01/BP1.4979 | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:Bioprojet | |||||||||||||
Full Title: Randomized placebo controlled trial assessing the efficacy and safety of BP1.4979 in smoking cessation | |||||||||||||
Medical condition: Smoking cessation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003695-23 | Sponsor Protocol Number: 69HCL14-0201 | Start Date*: 2015-07-21 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of inflammatory choroidal neovascularization in young subjects: the ALINEA study | |||||||||||||
Medical condition: inflammatory choroidal neovascularization | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005792-12 | Sponsor Protocol Number: GOIRC-06-2020 | Start Date*: 2022-04-05 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) | |||||||||||||
Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000018-16 | Sponsor Protocol Number: OZA22/IM047-048 | Start Date*: 2023-04-19 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005467-31 | Sponsor Protocol Number: 2020_843_0142 | Start Date*: 2021-01-28 |
Sponsor Name:CHU Amiens-Picardie | ||
Full Title: Effect of Tinzaparin on inflammatory biomarkers during the acute phase of deep vein thrombosis | ||
Medical condition: acute phase of deep vein thrombosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003627-54 | Sponsor Protocol Number: 150601 | Start Date*: 2016-05-11 | |||||||||||
Sponsor Name:Tecnimede, Sociedade Técnico-Medicinal, S.A. | |||||||||||||
Full Title: Randomized, multicenter, placebo-controlled, double blind study to assess the efficacy and tolerability of 2% diltiazem hydrochloride in the treatment of chronic anal fissure and a 24 week follow-u... | |||||||||||||
Medical condition: Cronic Anal fissure (CAF) The underlying pathogenesis of chronic anal fissure involves initial local trauma (generally caused by hard stools), resulting in a wound, internal anal sphincter spasm an... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004517-84 | Sponsor Protocol Number: ITFE-2026-C10 | Start Date*: 2015-02-26 |
Sponsor Name:ITF Research Pharma S.L.U | ||
Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL ... | ||
Medical condition: In postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effects; v... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003967-21 | Sponsor Protocol Number: MGT009 | Start Date*: 2017-06-09 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy of adults and children with X-linked Retinitis Pigme... | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003856-59 | Sponsor Protocol Number: MGT007 | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:MeiraGTX UK II Ltd | |||||||||||||
Full Title: Long-term follow-up study of participants following an open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/8-hCARp.hCNGB3) for gene thera... | |||||||||||||
Medical condition: Achromatopsia caused by mutations in the CNGB3 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008713-20 | Sponsor Protocol Number: BGC20-1531-04 | Start Date*: 2009-03-26 |
Sponsor Name:Danish Headache Center | ||
Full Title: EP4 receptor antagonism and PGE2 in a human headache model | ||
Medical condition: PGE2 will induce headache in healthy subjects and BGC20-1531 or placebo will be used to block the developement of headache. In the future BGC20-1531 might be a possible anti-migraine drug. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006940-69 | Sponsor Protocol Number: 601 | Start Date*: 2010-05-20 |
Sponsor Name:Lund University Hospital | ||
Full Title: Add-on treatment of mental illness with anti-viral medicine | ||
Medical condition: Schizophrenia, bipolar disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013619-36 | Sponsor Protocol Number: SINTRA-REV | Start Date*: 2009-11-02 | |||||||||||
Sponsor Name:Fundación General de la Universidad de Salamanca | |||||||||||||
Full Title: Estudio, multicéntrico, aleatorizado, doble ciego, fase III de Revlimid (Lenalidomida) versus placebo en pacientes con Síndrome Mielodisplasico de bajo riesgo (IPSS bajo e intermedio-1) con alterac... | |||||||||||||
Medical condition: Pacientes mayores de 18 años con Síndrome Mielodisplasico de bajo riesgo (IPSS bajo e intermedio-1) con alteración en 5q- y anemia sin necesidades transfusionales | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Ongoing) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003431-29 | Sponsor Protocol Number: MGT012 | Start Date*: 2019-06-24 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: An open label, multi-centre, Phase I/II dose escalation trial of an adeno-associated virus vector (AAV2/8-hG1.7p.coCNGA3) for gene therapy of children with achromatopsia owing to defects in CNGA3 | |||||||||||||
Medical condition: Achromatopsia caused by mutations in the CNGA3 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002349-12 | Sponsor Protocol Number: RALBAT | Start Date*: 2013-08-17 |
Sponsor Name:Unit of Infectious Diseases, Department of Medical Scieces, University of Torino c/o ASLTO2, Amedeo di Savoia Hospital | ||
Full Title: “Switching HIV-positive Women With Undetectable Viremia on Tenofovir/Emtricitabine plus Boosted Atazanavir to RALtegravir (400 mg twice-daily) plus Boosted ATazanavir (300/100 mg once-daily): A Pil... | ||
Medical condition: HIV infection, osteopenia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002290-35 | Sponsor Protocol Number: MGT006 | Start Date*: 2016-12-20 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/8-hCARp.hCNGB3) for gene therapy of adults and children with achromatopsia owing t... | |||||||||||||
Medical condition: Achromatopsia caused by mutations in the CNGB3 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001388-55 | Sponsor Protocol Number: CAPT | Start Date*: 2020-02-24 | |||||||||||
Sponsor Name:CONSORZIO ONCOTECH | |||||||||||||
Full Title: A Phase II Trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients | |||||||||||||
Medical condition: Metastatic Triple-negative PD-L1 positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002219-69 | Sponsor Protocol Number: CHUBX2019/49 | Start Date*: 2021-07-19 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Long-term iron chelation in the prevention of secondary degeneration after cerebral infarction | ||
Medical condition: Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
